Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

October 15, 2009 (Vol. 29, No. 18)

Fighting Pancreatic Cancer's Intractable Nature

Search for Markers Intensifying as Research Confirms that Early Detection Is Critical

  • This year has been disappointing for physicians and patients hoping for new treatment options for pancreatic cancer. Pfizer terminated its Phase III development of axitinib in pancreatic cancer in January. Sanofi-Aventis and Regeneron Pharmaceuticals also stopped their late-stage study of aflibercept for the same disease last month. Both ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.